Company news
Valneva Se (EURONEXT:VLA) news
Valneva Se news releases on 6ix. Latest, Oct 5, 2026: Declaration of shares and voting rights - Status as of September 30, 2026
Press releases & updates
Declaration of shares and voting rights - Status as of September 30, 2026
October 5, 2026
Declaration of shares and voting rights - Status as of August 31, 2026
September 4, 2026
Déclaration d’actions et de droits de vote - Statut au 31 août 2026
September 3, 2026
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
August 13, 2026
Valneva Half-Year 2026 Financial Report
August 12, 2026
Declaration of shares and voting rights - Status as of July 31, 2026
August 5, 2026
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
July 22, 2026
Declaration voting rights - June 30,2026
July 2, 2026
Valneva Announces Successful Outcome of its Annual General Meeting
June 25, 2026
Valneva Announces Availability of Documentation for its Annual General Meeting
June 4, 2026
VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026
June 3, 2026
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 13, 2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
May 6, 2026
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
May 5, 2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering
April 30, 2026
Declaration of shares and voting rights of Valneva SE – March 2026
April 3, 2026
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
March 26, 2026
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
March 23, 2026
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
March 18, 2026
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
March 18, 2026
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
March 9, 2026
VALNEVA Declaration of shares and voting rights: February 28, 2026
March 6, 2026
Valneva to Participate in Upcoming Investor Conferences
March 2, 2026
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
February 19, 2026
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
February 13, 2026
VALNEVA Declaration of shares and voting rights: January 31, 2026
February 11, 2026
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
February 3, 2026
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
January 19, 2026
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
January 9, 2026
Valneva SE - Declaration of voting rights - December 2025
January 8, 2026
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
December 31, 2025
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
December 10, 2025
VALNEVA Declaration of shares and voting rights: November 30, 2025
December 5, 2025
Valneva to Further Consolidate its Operations in France
November 26, 2025
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
November 26, 2025
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
November 20, 2025
VALNEVA Declaration of shares and voting rights: October 31, 2025
November 5, 2025
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
November 4, 2025
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
October 27, 2025
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
October 6, 2025
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
September 30, 2025
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
September 3, 2025
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
August 25, 2025
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
August 18, 2025
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
August 12, 2025
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
August 7, 2025
VALNEVA Declaration of shares and voting rights: July 31, 2025
August 5, 2025
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
July 29, 2025
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
July 11, 2025
VALNEVA Declaration of shares and voting rights: June 30, 2025
July 3, 2025